Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP

picture of <B>Alexandre</B> <B>Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP</B> <B> </B>

Professor and Founding Chair, Department of Clinical Pharmacy Practice
College of Health Sciences


Pharm.D., Rutgers University, 2004
Pharmacy Practice Residency, University of California San Francisco, 2005
Oncology Specialty Residency, University of California Davis Medical Center, 2006
M.P.H., National University of Singapore, 2011

ORCiD: 0000-0003-4391-4219

Phone: (949) 824-8896
Email: a.chan@uci.edu

University of California, Irvine
101 Theory, Suite 100
Mail Code: 3958
Irvine, CA 92697
Research Interests
supportive care, cancer survivorship, biomarkers, pharmacogenomics, oncology pharmacy, clinical pharmacy, drug-related problems, pharmacist
Appointments


Adjunct Associate Professor, Duke-NUS Medical School, Singapore, 2015-2020
Deputy Head, Department of Pharmacy, National University of Singapore, 2017-2019
Associate Professor (with Tenure), Department of Pharmacy, National University of Singapore, 2012-2019
Assistant Professor, Department of Pharmacy, National University of Singapore, 2007-2011
Lecturer, Department of Pharmacy, National University of Singapore, 2006-2007
Registered Pharmacist in California (USA), New Jersey (USA), Macau and Singapore

Research Abstract


Dually board certified in Pharmacotherapy (BCPS) and Oncology Pharmacy (BCOP), Dr. Chan has published >190 full-length peer-reviewed manuscripts in a wide array of cancer supportive care and survivorship topics, including chemotherapy-induced nausea and vomiting, myelosuppression, cancer-related cognitive impairment, dermatological toxicities and cancer-related fatigue. Dr. Chan's research program has attracted over $3 million USD of competitive funding support from governmental agencies, foundations and pharmaceutical companies. He has provided clinical training and research supervision to PharmD candidates, PhD candidates and fellows.

The overarching themes of Dr. Chan's research program are to (i) evaluate the mechanisms and biomarkers underlying these toxicities, (ii) understand the impact of these toxicities on patients’ quality of life, (iii) develop pharmacological and non-pharmacological interventions, as well as health services to effectively manage these side effects.

Dr. Chan’s research group was the first to establish the role of Brain Derived Neurotrophic Factor (BDNF) and its genetic polymorphism in chemobrain, and the findings were validated in a separate cohort. His research group has also evaluated the impact of other biomarkers (such as pro-inflammatory cytokines, mitochondrial DNA, dehydroepiandrosterone and leptin) on the various toxicities.

Dr. Chan has also served as Principal Investigator on numerous health-services and clinical research studies that were designed to improve symptom burden and quality of life in cancer patients and survivors. He has developed and trialed two multidisciplinary support programs that are designed to reduce symptom burden in breast cancer survivors and AYA cancer patients. Currently, he is conducting a RCT in Singapore to evaluate the role of a traditional Chinese medicine to manage cancer-related fatigue in cancer survivors (NCT04104113). He is also conducting two RCTs to evaluate the impact of an accessible cancer care program within a cancer center (ACCESS, NCT04014309) as well as an inter-professional community care model to manage breast cancer survivors (BASIC). Dr. Chan has also conducted numerous studies to evaluate the impact of drug-related problems, adverse drug reactions and unwanted hospital readmissions in both general and cancer population.

Dr. Chan has authored numerous textbook chapters in oncology and clinical pharmacy. His chapters were published in textbooks including Pharmacotherapy: A Pathophysiologic Approach, Pharmacotherapy Self-Assessment Program (PSAP) and Ambulatory Care Self-Assessment Program (ACSAP). Dr. Chan was awarded the Young Scientist Award by National University of Singapore in 2013, and the Steven M. Grunberg Memorial Award by Multinational Association of Supportive Care in Cancer (MASCC) in 2015. Dr. Chan is an elected Fellow of the American College of Clinical Pharmacy and the International Society of Oncology Pharmacy Practitioners (ISOPP). He is currently serving as the Past President for ISOPP and an Associate Editor for Journal of Oncology Pharmacy Practice.

Awards and Honors


Fellow, International Society of Oncology Pharmacy Practitioners (FISOPP), 2018
The SingHealth 10th Allied Health Innovative Practice Award, 2017
The Steven M. Grunberg Memorial Award, MASCC, 2015
Fellow, American College of Clinical Pharmacy (FCCP), 2014
The Young Scientist Award, Faculty of Science, NUS, 2013
The Ernest Little Award, Ernest Mario School of Pharmacy, 2004

Publications
 


Selected Peer Review Book Chapters

Chan A, Tan CJ, Sessions J. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 11th ed. New York, NY: McGraw-Hill. Chaper 149, 2020.

Chan A. Breast Cancer. In: Pharmacotherapy Self-Assessment Program (PSAP): Hematology/Immunology/Oncology Book 2; American College of Clinical Pharmacy; 132-152, 2018.

Chan A, Lee JYC. Cancer Survivorship. In: Ambulatory Care Self-Assessment Program (ACSAP) Book 1; American College of Clinical Pharmacy; 109-137, 2017.

Chan A, Sessions J. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. New York, NY: McGraw-Hill; Chapter 132; 2181-208; 2016.

Chan A, Yee GC. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, NY: McGraw-Hill; Chapter 109; 2009-36, 2014.

Chan A, Yee GC. Lymphomas. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; Chapter 140; 2333-59, 2011.

Iannucci A, Chan A. Management and Treatment of Hematologic Toxicities. In: Oncology Nursing-Pharmacy Handbook. Ignoffo RJ, Viele C, Ngo Z, eds. 1st ed. Elsevier-Mosby, 2007.

 


Selected Peer-Reviewed Publications (Ten Out of 200, please refer to Pubmed for full listing)

Chan A, Ashbury F, Fitch MI, Koczwara B, Chan RJ; MASCC Survivorship Study Group. Cancer Survivorship Care During COVID-19-perspectives and Recommendations From the MASCC Survivorship Study Group. Support Care Cancer 2020;28(8):3485-3488.

Alexander M, Jupp J, Chazan G, O'Connor S, Chan A. Global Oncology Pharmacy Response to COVID-19 Pandemic: Medication Access and Safety. J Oncol Pharm Pract 2020; doi: 10.1177/1078155220927450

Toh YL, Tan CJ, Yeo A, Shwe M, Ho K, Gan YX, Chu P, Olson K, Chan A. Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: a prospective cohort study. Journal of Cellular and Molecular Medicine 2019 ;23(6):4281-4289.

Toh YL, Shariq Mujtaba J, Bansal S, Yeo A, Shwe M, Lau AJ, Chan A. Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. Pharmacotherapy 2019;39(5):553-563.

Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe S, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KWJ, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and meta-analysis of the association between BDNF Val66Met polymorphism and cognitive impairment in patients receiving chemotherapy. Molecular Neurobiology 2018. Epub doi: 10.1007/s12035-018-1410-4

Chae JW, Ng R, Chan A. Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. Support Care Cancer 2018;26(11):3669-3670.

Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A. Distinct and Heterogeneous Trajectories of Self-perceived Cognitive Impairment among Asian Breast Cancer Survivors. Psychooncology 2018;27(4):1185-1192.

Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. Ann Oncol 2015;26(7):1446-51.

Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Association of drug exposure with toxicity and clinical response in metastatic renal-cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol 2015;10(3):429-37

Lee J, Chan A. Polypharmacy in the elderly cancer patient: clinical implications and management. Lancet Oncology 2011;12(13):1249-5

Professional Societies
International Society of Oncology Pharmacy Practitioners
Multinational Association of Supportive Care in Cancer
American College of Clinical Pharmacy
American Society of Clinical Oncology
Phi Delta Chi
Phi Lambda Sigma
Rho Chi
Other Experience
President
International Society of Oncology Pharmacy Practitioners 2018—2020

Past President
International Society of Oncology Pharmacy Practitioners 2020—2022

Board of Director
Multinational Association of Supportive Care in Cancer 2012—2020

Associate Editor
Journal of Oncology Pharmacy Practice 2010—Now

Editorial Board Member
Pharmacotherapy 2016—Now

Last updated
07/24/2020